Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02680561 · ClinicalTrials.gov registry record · Phase 1
A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma
A Phase 1 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02680561 is a Phase 1 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 20 participants.
The verdict
NCT02680561, a Phase 1 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of the study is to characterize the pharmacokinetic profiles of fluticasone propionate and/or salmeterol when delivered as a single oral inhalation dose of Fp MDPI and FS MDPI.
Interventions
- DRUG Fluticasone propionate/salmeterol
- DRUG Fluticasone Propionate MDPI
- DRUG Fluticasone Propionate/Salmeterol MDPI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-04 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02680561
The ClinicalTrials.gov registry entry for NCT02680561 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fluticasone propionate/salmeterol is the first listed.
NCT02680561 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02680561 about?
NCT02680561 is a clinical study titled "A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma". The purpose of the study is to characterize the pharmacokinetic profiles of fluticasone propionate and/or salmeterol when delivered as a single oral inhalation dose of Fp MDPI and FS MDPI.
What is the current status of trial NCT02680561?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2016-04. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02680561?
The interventions under investigation include: Fluticasone propionate/salmeterol (DRUG), Fluticasone Propionate MDPI (DRUG), Fluticasone Propionate/Salmeterol MDPI (DRUG).
Who is sponsoring clinical trial NCT02680561?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.